title: Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
abstract: Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. Besides, mammalian target of rapamycin inhibition has the ability to modulate T-lymphocyte homeostasis. Here, we report the case of a metastatic renal cell carcinoma patient treated with everolimus who presented unexpected prolonged tumor response. The monitoring of immune responses showed strong antitumor T-cell activation at the time of disease control, whereas a profound immunosuppression occurred when tumor progressed. Thus, a change of immune functions is associated with everolimus treatment. Our observation suggests that everolimus could shape immune responses, which in turn could contribute to its efficacy.
authors: *Oncologie, Besançon Cedex §CIC-BT506, CHRU †INSERM, UMR1098 ‡UMR1098, Université de Franche-Comté ∥EFS Bourgogne Franche-Comté ¶Laboratoire de Pharmacologie Clinique et Toxicologie, Besançon, France.
authors: Antoine
authors: A
authors: Thiery-Vuillemin
authors: Caroline
authors: C
authors: Laheurte
authors: Laura
authors: L
authors: Mansi
authors: Bernard
authors: B
authors: Royer
authors: Xavier
authors: X
authors: Pivot
authors: Christophe
authors: C
authors: Borg
authors: Olivier
authors: O
authors: Adotevi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D000068338:Everolimus; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D008213:Lymphocyte Activation / Q000276:immunology; D009362:Neoplasm Metastasis; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000068338:Everolimus; D020123:Sirolimus